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The odds of achieving a sustained virological response (SVR) in
patients with chronic hepatitis C with a therapy of pegylated
interferon-alpha (pegIFN-α) and ribavirin are still too low,
particularly in patients infected with hepatitis C virus (HCV)
genotypes 1 or 4.1–4 Therefore, intensive efforts have been made
to develop directly acting antiviral agents (DAAs) against HCV.5–12
Many of these DAAs are currently in phase I–III development and
will significantly change treatment options for HCV infection in the
near future. The most advanced compounds are telaprevir and
boceprevir, which are both inhibitors of the HCV NS3 protease 
and have been shown to significantly enhance SVR rates in HCV
genotype 1 patients when applied in addition to pegIFN-α 
and ribavirin.13–15
NS3/4A Protease Inhibitors
NS3/4A protease inhibitors can be divided into two chemical
classes: macrocyclic inhibitors and linear tetra-peptide α-ketoamid
derivatives. Ciluprevir has a macrocyclic structure and was the first
protease inhibitor evaluated in patients with chronic hepatitis C.
Ciluprevir, as well as subsequently developed NS3/4A protease
inhibitors of both molecular classes, strongly inhibited HCV
replication during monotherapy, but also frequently caused the
selection of resistant mutants, which may be followed by viral
breakthrough.12,16–18 Although the development of ciluprevir was
stopped because of serious cardiotoxicity observed in an animal
model, the proof of principle was provided for successful
suppression of HCV replication by NS3/4A inhibitors in patients with
chronic hepatitis C. Subsequent studies have shown that the
frequency of resistance development against protease inhibitors
can be vastly reduced by the additional administration of 
pegIFN and ribavirin. Telaprevir and boceprevir are the most
advanced NS3/4A protease inhibitors, and are currently in 
phase III evaluation.
Telaprevir (VX-950)
Telaprevir is an orally bioavailable NS3 protease inhibitor that
belongs to the α-ketoamids and that reversibly binds the enzyme
covalently, with a half-life of 58 minutes of the enzyme–inhibitor
complex. An initial double-blind, randomised, placebo-controlled
phase I clinical trial showed that telaprevir monotherapy >14 
days in HCV genotype 1 patients was well tolerated and led to 
a rapid decline of HCV RNA serum levels in all dosage groups.19
The best results were obtained in the 750mg telaprevir every 
eight hours (q8h) dose group with a median reduction of HCV RNA
of 4.4 log10 after 14 days of treatment, which is the basis for
telaprevir dosage in most of the subsequent clinical trials.
However, viral rebound due to selected mutants occurred in all
patients after treatment completion and in some patients even
during therapy.18 Subsequent phase I studies showed that the
addition of pegIFN-α and ribavirin to telaprevir leads to an even
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more pronounced HCV RNA decline and reduces the frequency of
telaprevir-resistant mutants and viral breakthrough.20,21 These
encouraging results led to the design of phase II clinical studies to
determine the impact of telaprevir in addition to pegIFN-α and
ribavirin on SVR rates.
Phase II Studies
Telaprevir and Pegylated Interferon with and without Ribavirin
Studies in Treatment-naïve Patients 
Larger phase II clinical trials (Efficacy of Pegylated Interferon on Liver
Fibrosis in Co-Infected Patient With HIV and Hepatitis C [PROVE] 1 and
2) in treatment-naïve genotype 1 patients assessed whether overall
treatment duration could be reduced and/or SVR rates be improved
with the addition of telaprevir to pegIFN-α-2a and ribavirin (see Figures
1 and 2). PROVE 1 was conducted in the US, whereas PROVE 2 was
conducted in Europe. In addition, a study comparing two- versus three-
times-daily administration of telaprevir in combination with either
pegIFN-α-2a or -2b (C208) and studies in genotype 2-, 3- and 4- infected
patients were performed (C209, C210).
In PROVE 1, telaprevir, pegIFN-α-2a and ribavirin were administered
for 12 weeks in combination followed by pegIFN-α-2a and ribavirin
alone for 0 (n=17), 12 (n=79) or 36 (n=79) weeks in comparison with
standard treatment. SVR rates were 35, 61 and 67%, respectively,
compared with 41% with standard treatment. According to the study
protocol, treatment was only stopped after 12 or 24 weeks when a
rapid virological response (RVR) was achieved. Serious adverse effects
led to premature treatment termination in 18% of all subjects treated
with telaprevir in contrast to 4% of patients with standard therapy.14
The study design of PROVE 2 was similar to that of PROVE 1, with the
main difference being that treatment termination after 12 or 24 weeks 
was independent of achieving an RVR and one treatment arm was
ribavirin-free. The recently published final results showed SVR rates
of 36, 60 and 69%, respectively, for patients treated with telaprevir
plus pegIFN alone for 12 weeks (n=78), telaprevir and pegIFN and
ribavirin for 12 weeks (n=82) and telaprevir, pegIFN and ribavirin for
12 weeks followed by 12 weeks of pegIFN plus ribavirin alone (n=81).
The SVR rate achieved by standard treatment was 46%. However, the
rate of relapse in the groups treated for 12 weeks was relatively high
at 30 and 48%, respectively, of all patients who were treated with and
without ribavirin. Two patients who discontinued treatment at days 60
and 65 experienced a late relapse 36 and 48 weeks after the end of
treatment, respectively.13
The results of PROVE 1 and 2 indicate that 12 weeks of triple therapy
was too short because of the high rate of relapse after treatment
completion. Moreover, ribavirin is necessary in therapies with
telaprevir to achieve high SVR rates. However, 24–48 weeks of total
therapy including 12 weeks of triple therapy with telaprevir in addition
to standard treatment greatly improved SVR rates in treatment-naïve
genotype 1 patients compared with the standard of care. RVR during
triple therapy is an important predictor of treatment success and can
be applied to define individualised treatment durations.
The most important side effects of telaprevir are rash, gastrointestinal
disorders and anaemia. Although severe rash may require treatment
discontinuation, moderate forms can be treated successfully with
topical steroids. The median decline of blood haemoglobin
concentration related to telaprevir was approximately 1g/dl. Since
telaprevir was administered in most trials for only 12 weeks, the use
of erythropoietin analogues was rarely necessary.
C208 was a small study (n=161) comparing three-times-daily 750mg
telaprevir in combination with pegIFN-α-2a or -2b plus ribavirin versus
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Combination therapy of telaprevir (TVR) and pegylated interferon-alpha-2a (pegIFN-α-2a) +
ribavirin (Riba) in treatment-naïve genotype 1 patients. 
Rel. = relapse; SVR = sustained virological response.
Figure 2: Results of PROVE 2 (Europe)
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Combination therapy of telaprevir (TVR) and pegylated interferon-alpha-2a (pegIFN-α-2a) ±
ribavirin (Riba) in treatment-naïve genotype 1 patients.
Rel. = relapse; SVR = sustained virological response; TW = treatment week.
Figure 3: Results of PROVE 3
Combination therapy of telaprevir (TVR) and pegylated interferon-alpha-2a (pegIFN-α-2a) ±
ribavirin (Riba) in hepatitis C virus (HCV) genotype 1 patients with prior non-response (NR) or
relapse (Rel.) to standard treatment. 
RVR = rapid virological response; SVR = sustained virological response. 
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Figure 1: Results of PROVE 1 (US)
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two-times-daily 1,125mg telaprevir in combination with pegIFN-α-2a or
-2b plus ribavirin.22 In all four treatment arms, similar SVR rates were
observed (81–85%). These high overall SVR rates underline the potential
of the triple-therapy approach. They are explained in part by
experienced study centres with very low discontinuation rates (5%) in
comparison with the PROVE studies. In addition, in this study the
response-guided therapy approach was investigated. Treatment
duration was shortened to 24 weeks in patients who achieved a RVR,
while the remaining patients received therapy for 48 weeks. Between 80
and 83% of all patients treated with pegIFN-α-2a and 67–69% of all
patients treated with pegIFN-α-2b achieved an RVR and could therefore
be treated for 24 weeks.
Studies in Non-responders and Relapsers
The PROVE 3 trial was conducted to determine SVR rates of treatment
with telaprevir in combination with pegIFN-α and ribavirin in
treatment-experienced patients (see Figure 3). Telaprevir was
administered in combination with pegIFN-α-2a with and without
ribavirin for 12–24 weeks followed by pegIFN-α-2a and ribavirin alone
for up to 24 weeks. Re-treatment of previous non-responders with 12
weeks of triple therapy followed by 12 weeks of standard treatment
led to an SVR rate of 51% (69% relapser, 39% non-responder), which is
significantly higher than the SVR rates achieved with the standard 
of care (14%). Re-treatment of non-responders with 24 weeks of 
triple therapy followed by 24 weeks of standard treatment led to an
SVR rate of 53% (76% relapser, 38% non-responder) and re-treatment
of non-responders with 24 weeks of telaprevir and pegIFN-α-2a
without ribavirin followed by 24 weeks of pegIFN-α-2a alone led to a
SVR rate of only 24% (42% relapser, 11% non-responder). The latter
result indicates that ribavirin is required for a successful treatment of
non-responders with telaprevir. As in the PROVE 1 and 2 studies, viral
breakthrough was observed more frequently in patients infected with
genotype 1a than in patients infected with genotype 1b.23
Phase III Studies
Design of Phase III Clinical Trials – Telaprevir with 
Pegylated Interferon-alpha and Ribavirin
Phase III clinical trials evaluating telaprevir in combination with 
pegIFN-α and ribavirin have been initiated. The A New Direction in HCV
Care: A Study of Treatment-Naive Hepatitis C Patients with telaprevir
(ADVANCE) trial enrolled more than 1,000 treatment-naïve HCV
genotype 1 patients to evaluate 24 weeks of telaprevir-based therapy.
Telaprevir was dosed at 750mg every eight hours and given for eight or
12 weeks in combination with pegIFN-α-2a and ribavirin followed by
pegIFN-α-2a and ribavirin alone until treatment week 24. Patients 
who did not achieve an RVR were treated with pegIFN-α-2a and ribavirin
until week 48. In the A Randomized Study of Stopping Treatment at 24
Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve
Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended
Rapid Viral Response (eRVR) While Receiving Telaprevir, Peginterferon
Alfa2a (Pegasys®) and Ribavirin (Copegus®) (ILLUMINATE) trial, telaprevir
was given for 12 weeks in combination with pegIFN-α-2a and ribavirin
followed by pegIFN-α-2a and ribavirin alone until treatment week 24 or
28. The aim of the ILLUMINATE trial is to assess whether treatment
extension beyond 24 weeks of total therapy improves SVR rates in
patients with RVR or EVR. The Re-treatment of Patients with Telaprevir-
based Regimen to Optimize Outcomes (REALIZE) study enrolled more
than 650 patients with prior failure on standard treatment. PegIFN-α-2a
and ribavirin was given for 48 weeks including 12 weeks of telaprevir at
a dose of 750mg every eight hours. In one treatment arm, telaprevir
treatment was initiated after a four-week lead-in phase of pegIFN-α-2a
and ribavirin alone. SVR data from the ADVANCE, ILLUMINATE and
REALIZE studies are expected to be published in 2010.
Viral Resistance to Telaprevir
Due to the high replication rate of HCV and the poor fidelity of its RNA-
dependent RNA polymerase, numerous variants (quasi-species) are
continuously produced during HCV replication. Among them, variants
carrying mutations altering the conformation of the binding sites of DAA
compounds can develop. During treatment with specific antivirals, these
pre-existing drug-resistant variants have a fitness advantage and can be
selected to become the dominant viral quasi-species with the
consequence of viral breakthrough. To date, mutations conferring
telaprevir resistance have been identified at four positions: V36A/M/L,
T54A, R155K/M/S/T and A156S/T1824–27 (see Table 1). The A156 mutation
was shown by in vitro analyses in the replicon assay, while the other
mutations could only be detected in vivo by a clonal sequencing
approach during telaprevir administration in patients with chronic
Hepatitis
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Table 1: Resistance Mutations to Hepatitis C Virus NS3 Protease Inhibitors
V36A/M T54S/A V55A Q80R/K R155K/T/Q A156S A156T/V D168A/V/T/H V170A/T
Telaprevir
* *
(linear)
Boceprevir
*
(linear)
SCH900518
(linear)
BILN-2061
(macrocyclic)
R7227/ITMN191
* *
(macrocyclic)
MK-7009
(macrocyclic)
TMC435350
(macrocyclic)
BI-201335
(macrocyclic?)
*Mutations associated with resistance in vitro but not described in patients. Blocks indicate resistance mutations against linear (dark blocks) or macrocyclic (light blocks) protease inhibitors
that were selected in patients during clinical studies and from in vitro studies.
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hepatitis C. The incidence of breakthrough of resistant mutants was
much lower during combination therapy of telaprevir and pegIFN-α-2a
in a 14-day study compared with telaprevir monotherapy. It is important
to note that up to three years after telaprevir treatment, low to medium
levels of V36 and R155 variants were still observed in single patients.28
As shown for other NS3/4A protease inhibitors as well (e.g. ITMN-
191), the genetic barrier to telaprevir resistance differs significantly
between HCV subtypes. In all clinical studies of telaprevir alone or in
combination with pegIFN-alfa and ribavirin, viral resistance and
breakthrough occurred much more frequently in patients infected
with HCV genotype 1a compared with genotype 1b. This difference
was shown to result from nucleotide differences at position 155 in
HCV subtype 1a (aga, encodes R) versus 1b (cga, also encodes R).
The mutation most frequently associated with resistance to
telaprevir is R155K; changing R to K at position 155 requires one
nucleotide change in HCV subtype 1a and two nucleotide changes in
subtype 1b isolates.29
Boceprevir (SCH 503034)
Boceprevir is another peptidomimetic orally bioavailable α-ketoamid
HCV protease inhibitor that forms a covalent but reversible complex
with the NS3 protein.30 Phase I clinical trials in HCV genotype 1 patients
with prior failure on standard therapy revealed that boceprevir
(100–400mg daily) monotherapy and combination therapy with 
pegIFN-α-2b resulted in mean maximum reductions in HCV RNA load of
up to 1.61 log10 and 2.88 log10, respectively.
31 Boceprevir was 
well-tolerated alone and in combination with pegIFN-α-2b. However,
viral breakthrough due to selection of pre-existing resistant 
mutants was observed in some patients, in particular during 
boceprevir monotherapy.32
Phase II Studies
Boceprevir and Pegylated Interferon with and without Ribavirin
Treatment-naïve Phase II Study
The aim of the HCV Serine Protease Inhibitor Therapy-1 (SPRINT 1) trial
was to investigate the safety, tolerability and antiviral efficacy of
boceprevir (800mg three times a day) in combination with pegIFN-α-2b
and ribavirin in treatment-naïve HCV genotype 1 patients.15 Treatment
with boceprevir in combination with pegIFN-α-2b and ribavirin was
performed either continuously for 28 or 48 weeks or for 24 or 44
weeks after a previous four-week lead-in phase of pegIFN-α-2b and
ribavirin alone. The lead-in design was chosen to determine a potential
benefit of pre-treatment with pegIFN-α-2b and ribavirin in terms of
avoiding resistance development. The control group was treated with
pegIFN-α-2b and ribavirin for 48 weeks. SVR rates after 28 weeks of
triple treatment were 54%, and 56% after 24 weeks with an additional
four weeks of pre-treatment lead-in with pegIFN-α-2 and ribavirin (see
Figure 4). SVR rates after 48 weeks of triple treatment were 67%, and
75% after 44 weeks with an additional four weeks of pre-treatment
lead-in with pegIFN-α-2b and ribavirin. After triple therapy for four
weeks with boceprevir, pegIFN and ribavirin, 38% of patients achieved
an RVR. The most common side effects related to boceprevir were
anaemia, nausea, vomiting and dysgeusia. In general, SPRINT-1 has
proved a higher antiviral efficacy of combination therapy with
boceprevir in comparison with the standard of care with slightly better
results after a four-week lead-in phase. However, RVR rates of only
38% during boceprevir triple therapy indicate that boceprevir is
potentially less potent than telaprevir, which, during triple therapy with
pegIFN-α-2b, led to an RVR rate of approximately 70%. 
Studies in Non-responders and Relapsers
In a complex study of HCV genotype 1 non-responders, the addition
of boceprevir to pegIFN-α-2b and ribavirin resulted in only 
slightly increased SVR rates compared with standard treatment (14%
versus 2%).33
Design of Phase III Studies
A phase III clinical trial (SPRINT-2) evaluating boceprevir in treatment-
naïve patients was recently initiated and has enrolled >1,000 patients.
Equivalent to the SPRINT-1 study design, patients received 800mg
boceprevir three times daily in combination with pegIFN-α-2b and
weight-based ribavirin for 28 or 48 weeks. The SCH 503034 Plus Peg-
Intron, With and Without Added Ribavirin, in Patients With Chronic
Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment
With Peginterferon Alfa Plus Ribavirin (RESPOND-2) study evaluated
boceprevir in combination with pegIFN-α-2b and ribavirin at the same
doses, but for 36 and 48 weeks in relapsers and partial responders. In
all investigational arms, a lead-in strategy with pegIFN-α-2b and
ribavirin is subsequently administered.
Viral Resistance to Boceprevir
In the replicon system, mutations at three positions conferring
boceprevir resistance were discovered (see Table 1). T54A, A156S
and V170A confer low-level resistance to boceprevir, whereas A156T,
which also confers telaprevir and ciluprevir resistance, exhibited
greater levels of resistance.34 In patients with chronic hepatitis C,
three additional mutations were detected during boceprevir
monotherapy (V36G/M/A, V55A and R155K).32
Other NS3 Protease Inhibitors
Other NS3 protease inhibitors are currently in phase I–II development
(R7227/ITMN191, MK7009, BI201335, TMC435350, SCH900518, BMS-
650032, PHX1766, ACH-1625).12,35,36 In general, they exhibit a high
antiviral activity in HCV genotype 1 patients, similar to telaprevir and
boceprevir. Potential advantages of these second-wave protease
inhibitors might be better tolerability, broader genotypic activity
and/or improved pharmacokinetics, which may allow a once-daily
dosage (e.g. TMC435).35
Triple-therapy studies for a number of compounds have been
initiated and confirm that resistance development is significantly
reduced by combination with pegIFN and ribavirin. Whereas linear
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Figure 4: Results of SPRINT-1
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tetrapeptide and macrocyclic inhibitors do not differ in general in
terms of their antiviral activity, their resistance profile differs
significantly. However, R155 is an overlapping position for resistance,
and different mutations at this amino acid site within the NS3
protease confer resistance to all protease inhibitors that are
currently in advanced clinical development.12
Compounds Targeting Hepatitis C 
Virus Replication
NS5B Polymerase Inhibitors
NS5B RNA polymerase inhibitors can be divided into two distinct
categories. Nucleoside analogue inhibitors (NAIs) such as
valopicitabine (NM283), R7128, R1626, PSI-7851 and IDX184 mimic
the natural substrates of the polymerase and are incorporated into
the growing RNA chain, thus causing direct chain termination by
tackling the active site of NS5B37-48. As the active centre of NS5B is
a highly conserved region of the HCV genome, NAIs are potentially
effective against all different genotypes, in contrast to NS3/4A
inhibitors. Moreover, single amino acid substitutions in every
position of the active centre may result in loss of function. Thus,
there is a relatively high genetic barrier in the development of
resistance to NAIs. 
In contrast to NAIs, the heterogeneous class of non-nucleoside
inhibitors (NNIs) bind to different allosteric enzyme sites, which results
in conformational protein change before the elongation complex is
formed.49 NS5B is structurally organised in a characteristic ‘right-hand
motif’ (see Figure 5) containing finger, palm and thumb domains, and
offers at least four NNI-binding sites, a benzimidazole (thumb 1)-binding,
thiophene (thumb 2)-binding, benzothiadiazine (palm 1)-binding and
benzofuran-(palm 2)-binding site.49,50 Theoretically, NNIs targeting
different binding sites can be used in combination or in sequence to
manage the development of resistance. As NNIs bind distantly to the
active centre of NS5B, their application results more frequently in
resistance development than during treatment with NAIs. In addition,
mutations at the NNI-binding sites do not necessarily lead to impaired
function of the enzyme. 
Nucleoside Analogues
Valopicitabine (NM283, 2’-C-methylcytidine/NM107) was the first
nucleoside inhibitor investigated in patients with chronic hepatitis C.
The antiviral activity of valopicitabine was low.51 The clinical
development of valopicitabine was stopped due to gastrointestinal
side effects and an insufficient risk–benefit profile.
The second nucleoside inhibitor investigated in patients with chronic
hepatitis C was R1626 (4’-azidocytidine/PSI-6130). A phase I study
showed high antiviral activity at high doses of R1626 in patients
infected with HCV genotype 1.44–46 No viral breakthrough with selection
of resistant variants was reported from monotherapy or combination
studies with pegIFN ± ribavirin. However, severe lymphopenia 
and infectious disease adverse events led to R1626 development
being stopped. 
R7128 is another nucleoside polymerase inhibitor with potent
antiviral activity during monotherapy in HCV genotype 1 patients.
Currently, R7128 is being investigated in phase II clinical trials in
HCV genotype 1-, 2- and 3-infected patients in combination with
pegIFN and ribavirin.39 No resistance development against R7128
was observed during both monotherapy and combination therapy
with pegIFN and ribavirin. Other NAIs of the NS5B polymerase 
(PSI-7851 and IDX184) are being evaluated in phase I clinical trials in
patients with chronic hepatitis C and many compounds are in pre-
clinical development.12
Non-nucleoside Analogues
Non-nucleoside Inhibitors – Site 1 Inhibitors 
(Thumb 1/Benzimidazole Site)
BILB1941, BI207127 and MK-3281 are NNI-site 1 inhibitors that have
been investigated in clinical phase I trials and exhibit low to medium
antiviral activities.12,52,53 No selection of resistant variants and viral
breakthrough has been observed during five days of treatment with
BILB1941 or BI207127. 
Non-nucleoside Inhibitors – Site 2 Inhibitors 
(Thumb 2/Thiophene Site)
Filibuvir (PF-00868554) is a NNI-site 2 inhibitor with medium antiviral
activity in a phase I study. In a subsequent trial, viral breakthrough
was observed in five out of 26 patients during combination therapy
with pegIFN-α-2a and ribavirin for four weeks.53
Other NNI-site 2 inhibitors that were evaluated in phase I trials 
are VCH-759, VCH-916 and VCH-22212.54 As with treatment with
filibuvir, VCH-759 and VCH-916 application resulted in viral
breakthroughs with selection of resistant variants, indicating a low
genetic barrier to resistance of these agents. 
Non-nucleoside Inhibitors – Site 3 Inhibitors 
(Palm 1/Benzothiadiazine Site)
ANA598 is a NNI-site 3 inhibitor that displayed antiviral activity during
treatment of HCV genotype-1-infected patients. No viral breakthrough
was observed during a short-term monotherapy trial.55
Non-nucleoside Inhibitors – Site 4 Inhibitors 
(Palm 2/Benzofuran Site)
Monotherapy with the NNI-site 4 inhibitor HCV-796 showed low
antiviral activity in HCV genotype-1-infected patients and resulted in
selection of resistant variants and viral breakthrough in several
patients.56 GS-9190 displays a low antiviral activity in a clinical study
and variants conferring resistance were identified in the beta-hairpin
of the polymerase. 
Hepatitis
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Figure 5: Structure of the Hepatitis C Virus NS5B RNA
Polymerase and Binding Sites
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NNI = Non-nucleoside inhibitor; NI = Nucleoside inhibitor.
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NS5A Inhibitors
In a single ascending-dose study, it was shown that inhibition of the
NS5A protein with BMS-790052 leads to a sharp initial decline of HCV
RNA concentrations.57 BMS-790052 binds to domain I of the NS5A
protein, which was shown to be important for regulation of HCV
replication. No clinical data on resistance to this class of drugs have
been presented yet and the results of multiple-dose and combination
therapy studies are awaited.
Directly Acting Antiviral Agents and 
Hepatitis C Virus Genotype
As the amino acid sequence of the NS3 protease domain varies
significantly between HCV genotypes, protease inhibitors may have a
different antiviral efficacy in patients infected with different HCV
genotypes. Indeed, telaprevir was less effective in treatment-naïve
patients infected with genotypes other than genotype 1. For HCV
genotype 2, a somewhat weaker antiviral activity in comparison with
HCV genotype 1 was observed with a mean viral decline of 3.9 log10
IU/ml during 14 days of monotherapy with telaprevir. 
In genotype-3- and 4-infected patients, no significant antiviral activity
was detectable (0.5–0.9 log10 decline).
58,59 In contrast to NS3, the active
centre of NS5B is a highly conserved region of the HCV genome. 
Thus, NAIs of NS5B have been shown to be effective across different 
HCV genotypes.60
Combination Therapies of Specific Antivirals
It is a fundamental question whether SVR can be achieved by
combination therapies of different specifically targeted antiviral
therapy for hepatitis C (STAT-C) compounds without pegIFN-α and
ribavirin A first clinical trial (INFORM-1 study) evaluated the
combination of a polymerase inhibitor (R7128) and an NS3 inhibitor
(R7227/ITMN191). In this proof-of-principle study, patients were
treated with both compounds for up to two weeks. HCV RNA
concentrations decreased up to 5.2 log10 IU/ml, no viral break-through
was observed and HCV RNA was undetectable at the end of dosing in
up to 63% of treatment-naïve patients.61 Future clinical trials need to
address whether long-term suppression of HCV replication or even
SVR can be achieved with such direct antiviral combination therapies.
Currently, combination studies with several compounds are being
conducted (R7128+R7227, VX-950+VCH222, BMS790052+ BMS650032,
BI201335+BI207127).
Conclusions 
Numerous DAA agents are currently under clinical phase I–III
evaluation. Monotherapy with most of these agents will be not suitable
since it frequently results in the selection of resistant variants, which
may cause viral breakthrough. R155 is an overlapping mutation
conferring resistance to all clinically evaluated protease inhibitors.
However, results of phase II clinical trials evaluating the most advanced
compounds, telaprevir and boceprevir, indicate that the addition of
these NS3/4A protease inhibitors to pegIFN-α and ribavirin substantially
improves the chance of achieving an SVR in treatment-naïve HCV
genotype 1 patients and in prior non-responders and relapsers to
standard therapy. In addition, at least during treatment with telaprevir-
based regimens, overall treatment durations can be shortened
significantly. Additional findings of the milestone studies PROVE 1 and
2 were that ribavirin is still necessary in HCV protease-inhibitor-based
therapy to achieve high SVR rates, and RVR during triple therapy is an
important predictor of treatment success and can be applied to define
individualised treatment durations. As DAA agents are burdened with
additional side effects such as anaemia, rash or gastrointestinal
disorders, there will likely be a debate as to which HCV genotype 1
patients require a triple-therapy approach. In this context, the impact of
recently discovered polymorphisms near the IL28B gene on SVR rates
during triple therapy as well as of other classic predictors of virological
response, such as baseline viral load, needs to be characterised in
future studies.62–64 Compared with NS3/4A protease inhibitors, most
HCV polymerase inhibitors display a lower antiviral activity during
monotherapy, and SVR data of triple therapies containing NS5B
inhibitors are awaited. However, some polymerase inhibitors are
equally effective against different HCV genotypes, whereas it was
shown that protease inhibitors such as telaprevir are less potent in
genotypes other than HCV genotype 1. In addition, NS5B inhibitors, at
least of the nucleoside analogue family, display a high genetic barrier
to resistance. Combination of different DAA agents may be sufficient 
to achieve an SVR or to suppress HCV during long-term application in
IFN-free regimens, which has to be proved in future studies. An
additional task for future research will be the identification of DAA
agents efficient for genotypes other than HCV genotype 1. n
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